page
tabl
studi
design
openlabel
phase
studi
evalu
safeti
toler
immunogen
vaccin
regimen
investig
plasmid
dna
vaccin
encod
hemagglutinin
ha
influenza
viru
studi
particip
offer
receiv
addit
option
booster
immun
licens
inactiv
monoval
influenza
vaccin
hypothesi
dna
vaccin
safe
human
administr
elicit
antibodi
respons
primari
object
evalu
safeti
toler
dna
vaccin
dosag
mg
administ
schedul
secondari
object
evalu
antibodi
respons
includ
induc
antibodi
titer
measur
hemagglutin
inhibit
hai
assay
document
reactogen
inactiv
influenza
vaccin
administ
subject
previous
vaccin
dna
vaccin
exploratori
object
relat
evalu
humor
cellular
immun
respons
includ
respons
inject
boost
licens
inactiv
influenza
vaccin
vaccin
develop
manufactur
vrc
niaid
compos
closedcircular
dna
plasmid
cmvr
promot
encod
hemagglutinin
influenza
viru
identifi
late
northern
hemispher
nh
influenza
season
refer
swine
flu
news
report
vaccin
vial
suppli
mgml
mg
dosag
requir
ml
inject
vaccin
dna
vaccin
administ
intramuscularli
im
deltoid
muscl
use
biojector
needlefre
inject
manag
system
biojector
licens
inactiv
monoval
influenza
vaccin
obtain
nih
clinic
center
cc
pharmaci
use
booster
inject
administ
needl
syring
brand
administ
depend
upon
avail
nih
cc
total
healthi
adult
year
age
rang
enrol
howev
subject
year
old
age
rang
subject
receiv
inject
dna
vaccin
shown
schedul
subject
may
enrol
first
week
studi
follow
enrol
remaind
subject
may
enrol
without
restrict
enrol
rate
subject
contraind
licens
inactiv
vaccin
addit
blood
draw
offer
option
receiv
licens
inactiv
influenza
vaccin
studi
includ
clinic
visit
telephon
contact
well
addit
visit
subject
opt
receiv
inactiv
influenza
vaccin
subject
receiv
inactiv
vaccin
outsid
vrc
clinic
studi
week
may
consent
contribut
addit
research
sampl
complet
extra
visit
schedul
post
boost
evalu
target
window
inactiv
vaccin
shown
schema
howev
given
subject
beyond
studi
week
earliest
mutual
conveni
date
vaccin
suppli
amend
protocol
becom
avail
accept
administr
option
inject
ad
postboost
research
sampl
collect
schedul
occur
rel
date
booster
inject
vaccin
inject
schedul
influenza
negativestrand
ribonucl
acid
rna
viru
belong
famili
orthomyxovirida
three
genera
influenza
circul
natur
influenza
b
c
first
two
known
caus
epidem
influenza
virus
encod
rna
gene
segment
classifi
basi
antigen
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
sixteen
ha
subtyp
na
subtyp
known
exist
three
ha
subtyp
two
na
subtyp
caus
signific
human
epidem
public
health
burden
influenza
world
enorm
annual
influenza
epidem
caus
death
worldwid
circul
virus
chang
quickli
reassort
creat
new
virus
present
immedi
threat
public
health
requir
develop
new
vaccin
signific
public
health
impact
influenza
infect
compound
potenti
pandem
caus
emerg
viru
strain
littl
preexist
immun
popul
sever
worldwid
outbreak
influenza
happen
last
centuri
novel
swineorigin
influenza
viru
soiv
identifi
caus
multipl
recent
case
infect
worldwid
exact
origin
viru
still
unclear
howev
tripl
reassort
swine
influenza
virus
contain
human
swine
avian
influenza
viru
compon
identifi
pig
unit
state
late
june
total
confirm
probabl
human
case
novel
influenza
death
associ
identifi
unit
state
http
june
world
health
organ
rais
worldwid
pandem
alert
level
phase
indic
global
pandem
develop
viru
spread
countri
yet
uncertain
time
seriou
sever
novel
pandem
experi
viru
limit
influenza
virus
known
acquir
multipl
chang
short
period
time
upon
migrat
new
host
unusu
patholog
novel
influenza
strain
includ
diarrhea
vomit
patient
predomin
infect
patient
popul
year
old
younger
joint
effort
scientif
commun
result
swift
identif
submiss
first
set
novel
influenza
sequenc
nation
center
biotechnolog
inform
ncbi
phylogenet
analysi
current
isol
center
diseas
control
prevent
cdc
show
soiv
genom
contain
six
gene
segment
pa
ha
np
ns
somewhat
similar
genom
describ
swine
triplereassort
virus
gene
encod
neuraminidas
na
matrix
protein
found
mostli
relat
influenza
virus
circul
swine
popul
eurasia
also
confirm
particular
combin
influenza
viru
gene
segment
seen
annual
world
health
organ
make
recommend
composit
season
influenza
vaccin
independ
recommend
northern
hemispher
nh
southern
hemispher
sh
consid
differ
time
base
epidemiolog
data
current
licens
influenza
vaccin
consist
compon
influenza
b
viru
strain
vaccin
includ
inactiv
influenza
vaccin
propag
embryon
chicken
egg
efficaci
vaccin
depend
upon
laborintens
method
product
limit
manufactur
capac
recent
spread
potenti
pandem
highli
pathogen
subtyp
novel
swine
origin
subtyp
alreadi
becam
pandem
rais
seriou
concern
influenza
pandem
event
pandem
influenza
strain
associ
greater
usual
morbid
mortal
current
avail
vaccin
product
methodolog
would
unabl
meet
worldwid
public
health
need
also
antigen
evolut
may
necessit
agil
rapidli
scalabl
product
process
effort
overcom
limit
eggbas
influenza
vaccin
product
method
manufactur
includ
baxter
sanofi
chiron
gsk
develop
cellbas
influenza
vaccin
influenza
vaccin
grown
canin
kidney
cell
mdck
line
manufactur
solvay
pharmaceut
licens
europ
inactiv
monoval
whole
viru
influenza
vaccin
produc
vero
cell
baxter
bioscienc
gener
neutral
antibodi
divers
strain
healthi
men
women
age
year
rate
advers
event
rate
seroconvers
level
immunogen
follow
twodos
regimen
rang
g
compar
describ
eggderiv
product
sever
new
technolog
undergon
evalu
hundr
research
subject
clinic
studi
includ
protein
subunit
vaccin
direct
influenza
virus
includ
avian
influenza
strain
protein
scienc
corpor
virosom
lipid
antigenpres
system
solvay
pharmaceut
adenovir
vector
vaccin
vaxin
epiderm
deoxyribonucl
acid
dna
vaccin
coat
onto
gold
bead
deliv
powderject
devic
technolog
includ
live
attenu
vaccin
recombin
particul
vaccin
influenza
protein
assembl
viruslik
particl
preclin
stage
evalu
evalu
clinic
trial
februari
meet
report
underscor
need
new
broadspectrum
influenza
vaccin
capabl
induc
longlast
immun
respons
meet
particip
recommend
plasmid
dnabas
technolog
assess
altern
convent
influenza
vaccin
product
strategi
plasmid
dnabas
vaccin
demonstr
preclin
efficaci
fast
rel
easi
manufactur
process
plasmid
dna
quickli
modifi
carri
antigen
interest
process
effici
cumbersom
costli
lengthi
tradit
process
involv
inactiv
purif
concentr
nativ
modifi
ha
antigen
recent
emerg
new
pandem
influenza
viru
methodolog
timelin
vaccin
develop
product
becom
urgent
issu
take
six
month
identif
pandem
influenza
strain
product
first
dose
vaccin
use
licens
technolog
delay
product
could
result
poor
growth
viru
strain
use
make
vaccin
recombin
dna
technolog
allow
much
faster
develop
product
vaccin
candid
base
viral
genom
sequenc
test
potenti
vaccin
candid
phase
clinic
studi
may
provid
urgent
need
data
immunogen
novel
influenza
strain
clarifi
exposur
influenza
subtyp
may
offer
cross
protect
disadvantag
current
dna
vaccin
may
take
sever
inject
gener
immun
respons
magnitud
durabl
consid
adequ
protect
therefor
beyond
proof
concept
aspect
demonstr
abil
rapidli
produc
vaccin
develop
way
induc
desir
immun
respons
singl
immun
may
need
futur
dna
vaccin
induc
balanc
immun
respons
address
humor
immun
also
trigger
cell
respons
may
effici
target
crossreact
viral
cell
epitop
therefor
potenti
vaccin
prototyp
rapidli
chang
viral
environ
warrant
investig
dna
vaccin
ha
may
elicit
crossreact
cell
respons
conserv
region
antigen
antigen
drift
characterist
influenza
virus
limit
abil
virusspecif
antibodi
neutral
emerg
viral
variant
howev
tcell
respons
conserv
viral
epitop
crossreact
may
provid
level
protect
serolog
distant
strain
also
suggest
cell
respons
import
correl
influenza
vaccin
protect
especi
elderli
popul
immun
season
flu
vaccin
use
store
serum
specimen
collect
previou
vaccin
studi
cdc
assess
level
crossreact
antibodi
novel
influenza
viru
cohort
children
adult
vaccin
influenza
season
vaccin
result
indic
adult
older
year
adult
age
year
crossreact
antibodi
novel
influenza
crossreact
antibodi
found
children
result
also
suggest
although
vaccin
adult
season
influenza
vaccin
gener
result
small
increas
antibodi
novel
influenza
current
season
vaccin
unlik
provid
protect
novel
influenza
viru
product
design
base
concept
immun
gene
transfer
plasmid
dna
vaccin
intend
use
prevent
vaccin
infect
novel
influenza
soiv
strain
plasmid
drug
substanc
follow
vrc
singl
plasmid
express
ha
protein
influenza
genbank
investig
vaccin
research
center
vrc
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
bethesda
md
develop
plasmid
dna
vaccin
strategi
demonstr
protect
immun
respons
influenza
preclin
studi
vaccin
platform
test
safeti
immunogen
human
clinic
trial
provid
technolog
platform
develop
addit
influenza
vaccin
product
use
either
singl
agent
part
primeboost
regimen
dna
plasmid
vaccin
prime
follow
recombin
adenovir
vector
boost
vaccin
express
influenza
b
strain
nucleoprotein
np
gene
induc
protect
immun
mice
preclin
human
safeti
data
support
evalu
plasmid
dna
vaccin
clinic
trial
investig
influenza
vaccin
vaccin
encod
ha
protein
mix
encod
season
influenza
strain
similar
reason
prior
human
experi
vaccin
provid
investig
brochur
background
experi
dna
vaccin
addit
preclin
andor
human
safeti
data
plasmid
dna
vaccin
encod
viral
protein
vaccin
human
immunodefici
viru
hiv
vaccin
vrc
vaccin
vaccin
vaccin
ebola
viru
vaccin
vaccin
vaccin
sever
acut
respiratori
syndrom
sar
viru
vaccin
vaccin
two
west
nile
viru
vaccin
vaccin
marburg
viru
vaccin
vaccin
undergon
current
evalu
phase
clinic
trial
healthi
adult
age
rang
year
year
old
depend
upon
studi
major
subject
year
age
rang
overal
vrc
dna
vaccin
safe
well
toler
popul
healthi
adult
year
old
vrc
dna
vaccin
construct
either
cytomegaloviru
cmv
cmvr
plasmid
backbon
ten
vaccin
dna
hiv
vaccin
ebola
viru
vaccin
sar
vaccin
second
wnv
viru
vaccin
marburg
vaccin
avian
pandem
season
influenza
vaccin
use
cmvr
promot
first
ebola
viru
dna
vaccin
first
vrc
dna
vaccin
cmvr
promot
enter
clinic
studi
hiv
dna
vaccin
cmvr
promot
provid
largest
experi
date
vrc
dna
vaccin
construct
evalu
extramur
phase
iii
studi
conduct
us
intern
cumul
studi
subject
vaccin
vrc
dna
vaccin
dosag
mg
administ
major
inject
mg
dosag
result
follow
clinic
trial
perform
vrc
clinic
publish
vrc
vrc
vrc
vrc
data
two
doseescal
studi
vrc
vrc
indic
mg
dosag
offer
combin
good
safeti
profil
greater
eas
administr
mg
dosag
reliabl
immunogen
indic
laboratori
measur
immun
respons
preclin
clinic
evalu
date
sever
plasmid
dna
vaccin
support
safeti
immunogen
dna
vaccin
administ
mg
dosag
mg
dosag
dna
influenza
vaccin
also
select
studi
influenza
avian
influenza
west
nile
viru
correl
protect
immun
effect
vaccin
expect
induct
neutral
antibodi
nab
nab
strongli
associ
recoveri
natur
sar
infect
although
efficaci
studi
yet
perform
human
dna
vaccin
first
vrc
clinic
trial
wnv
vaccin
vrc
provid
evid
dna
vaccin
induc
neutral
antibodi
studi
subject
receiv
dna
vaccin
develop
neutral
antibodi
wnv
assess
report
viru
particl
rvp
neutral
antibodi
assay
plaqu
reduct
neutral
test
prnt
vrc
sar
vaccin
studi
also
show
dna
vaccin
induc
neutral
antibodi
vrc
initi
design
protocol
vrc
phase
studi
evalu
safeti
toler
immunogen
vaccin
regimen
investig
plasmid
dna
vaccin
encod
ha
influenza
strain
time
studi
initi
enrol
licens
inactiv
pandem
influenza
vaccin
limit
suppli
access
gener
restrict
particular
risk
group
vrc
studi
fulli
enrol
novemb
januari
schedul
dna
vaccin
inject
administ
nih
clinic
center
pharmaci
expect
abl
obtain
licens
inactiv
vaccin
februari
gener
use
studi
particip
may
interest
receiv
vaccin
wide
avail
propos
offer
option
studi
inject
way
also
opportun
observ
effect
immun
respons
understand
vaccinolog
dna
prime
inactiv
vaccin
boost
influenza
antigen
studi
subject
receiv
licens
vaccin
outsid
vrc
clinic
studi
week
may
also
consent
addit
research
sampl
collect
expand
followup
visit
schedul
blood
specimen
evalu
immunogen
taken
baselin
specifi
time
point
hemagglutinin
specif
antibodi
measur
hai
assay
conduct
store
sampl
studi
week
preimmun
week
inject
secondari
object
studi
detect
antibodi
hai
assay
base
previous
describ
method
optim
detect
antibodi
strain
adult
studi
subject
like
preexist
immun
respons
influenza
ha
antigen
effect
vaccin
cell
respons
interest
varieti
exploratori
evalu
immunogen
may
also
perform
aspecif
cell
respons
measur
intracellular
cytokin
stain
ic
assay
enzymelink
immunospot
elispot
assay
antibodi
assay
well
assay
evalu
crossreact
elicit
immun
respons
may
perform
timepoint
throughout
studi
exploratori
evalu
ic
assay
base
upon
previous
publish
method
quantit
frequenc
cell
produc
interferongamma
respons
pool
overlap
peptid
repres
specif
antigen
specif
peptid
also
use
detect
tcell
respons
elispot
assay
modifi
previous
publish
method
addit
evalu
b
cell
respons
week
first
third
booster
studi
vaccin
perform
use
b
cell
elispot
assay
determin
proport
b
cell
secret
antigenspecif
antibodi
detect
antigenspecif
b
cell
base
previous
describ
method
may
differenti
b
cell
secret
differ
type
immunoglobulin
interim
immunoanalysi
perform
week
vaccin
first
subject
guid
plan
studi
research
sampl
immunogen
assay
process
niaid
vaccin
immun
tcell
antibodi
laboratori
nvital
gaithersburg
md
mani
immunogen
assay
also
perform
immunogen
assay
may
perform
vrc
laboratori
bethesda
md
approv
contract
laboratori
includ
bioqual
inc
rockvil
md
approv
research
collabor
drug
substanc
consist
one
closedcircular
plasmid
dna
macromolecul
vrc
express
influenza
ha
sequenc
deriv
human
isol
influenza
viru
plasmid
cmvr
promot
consist
translat
enhanc
region
cmv
immedi
earli
region
enhanc
cmvie
substitut
untransl
human
tcell
leukemia
viru
type
region
human
tcell
leukemia
viru
type
long
termin
repeat
manufactur
vrcniaidvaccin
pilot
plant
vpp
use
plasmid
dna
receiv
vrc
produc
clinic
trial
materi
current
good
manufactur
practic
cgmp
process
manufactur
fill
packag
summar
investig
brochur
ib
briefli
plasmid
use
master
cell
bank
mcb
synthes
vrc
use
blue
heron
biotechnolog
inc
bothel
wa
human
prefer
codon
previous
describ
plasmid
transfer
vpp
sequenc
confirm
use
cgmp
product
process
plasmid
use
transform
escherichia
coli
bacteri
host
strain
order
produc
individu
mcb
mcb
expand
cultur
inocul
fermentor
product
bacteri
cell
growth
depend
upon
cellular
express
kanamycin
resist
protein
encod
portion
plasmid
dna
follow
growth
bacteri
cell
harbor
plasmid
plasmid
dna
purifi
cellular
compon
concentr
filter
membran
store
formul
drug
product
final
vaccin
product
meet
lot
releas
specif
prior
administr
drug
product
manufactur
mg
dose
phosphat
buffer
salin
pb
vial
asept
fill
volum
ml
mgml
plasmid
preclin
pharmacolog
toxicolog
pharmacokinet
metabol
studi
conduct
influenza
dna
vaccin
extens
clinic
experi
dna
vaccin
construct
use
plasmid
backbon
cmvr
promot
includ
dna
vaccin
encod
influenza
antigen
see
section
nonglp
preclin
studi
conduct
mice
confirm
immunogen
product
express
ha
pandem
soiv
conclud
product
immunogen
induc
neutral
antibodi
mice
briefli
plasmid
dna
express
ident
amino
acid
ha
sequenc
novel
pandem
swineorigin
viru
vaccin
product
use
immun
control
anim
vaccin
empti
cmvr
plasmid
dna
plasmid
immun
mice
immun
plasmid
vrc
express
influenza
ha
sequenc
deriv
human
influenza
viru
isol
plasmid
synthes
vrc
use
human
prefer
codon
previous
describ
two
group
mice
per
group
immun
im
needl
syring
week
vrc
plasmid
empti
cmvr
plasmid
volum
blood
collect
day
immun
serum
isol
determin
neutral
antibodi
nab
titer
neutral
antibodi
nab
evalu
antisera
immun
mice
assess
neutral
activ
incub
pseudotyp
lentivir
report
vector
encod
luciferas
percent
neutral
calcul
reduct
luciferas
activ
rel
valu
achiev
presenc
preimmun
sera
previous
describ
antisera
immun
neg
control
mice
immun
empti
cmvr
plasmid
alon
show
nab
activ
howev
vaccin
dose
ha
plasmid
elicit
neutral
antibodi
inhibit
viral
entri
dilut
figur
nab
activ
boost
follow
administr
rd
dose
dna
vaccin
inhibit
viral
entri
least
dilut
figur
licens
inactiv
monoval
influenza
vaccin
avail
nih
clinic
center
pharmaci
use
booster
inject
inform
fda
licens
vaccin
avail
follow
link
http
purpos
studi
evalu
safeti
toler
immunogen
recombin
dna
vaccin
healthi
adult
year
old
evalu
safeti
toler
dna
vaccin
administ
im
biojector
dosag
mg
schedul
healthi
adult
year
old
evalu
antibodi
respons
includ
induc
antibodi
titer
measur
hai
assay
week
third
inject
document
reactogen
inactiv
influenza
vaccin
administ
subject
previous
vaccin
dna
vaccin
exploratori
object
relat
evalu
humor
cellular
immun
respons
cell
b
cell
includ
respons
inject
boost
licens
inactiv
vaccin
antibodi
evalu
hai
assay
timepoint
follow
inject
boost
licens
inactiv
influenza
vaccin
option
exploratori
interim
immunoanalysi
complet
first
subject
week
post
vaccin
guid
plan
studi
openlabel
phase
studi
adult
year
old
evalu
safeti
toler
immunogen
vaccin
regimen
investig
plasmid
dna
vaccin
encod
hemagglutinin
influenza
strain
studi
schema
shown
tabl
includ
option
booster
inject
licens
inactiv
vaccin
target
window
inactiv
vaccin
shown
schema
howev
given
subject
beyond
studi
week
earliest
mutual
conveni
date
licens
vaccin
suppli
amend
protocol
becom
avail
accept
administr
option
inject
ad
postboost
research
sampl
collect
schedul
interv
time
rel
date
booster
inject
subject
receiv
vaccin
outsid
studi
may
consent
contribut
addit
research
sampl
postboost
well
hypothesi
dna
vaccin
safe
human
administr
elicit
antibodi
respons
studi
conduct
vrc
clinic
niaid
nih
clinic
center
approv
satellit
facil
eg
mobil
clinic
trial
unit
mctu
vrc
clinic
cedar
lane
vaccin
occur
nih
clinic
center
safeti
vaccin
evalu
schedul
studi
visit
studi
subject
report
estim
durat
subject
complet
immun
followup
week
maintain
balanc
age
distribut
subject
subject
year
old
age
rang
enrol
subject
across
full
year
old
age
rang
enrol
simultan
subject
may
enrol
first
week
studi
follow
enrol
remaind
subject
may
enrol
without
restrict
enrol
rate
healthi
subject
age
year
recruit
institut
review
board
irb
approv
advertis
screen
vrc
screen
protocol
healthi
subject
interest
particip
vaccin
clinic
trial
specif
elig
requir
vaccin
studi
confirm
prior
enrol
subject
screen
educ
consent
process
occur
prior
enrol
ensur
subject
comprehend
purpos
detail
studi
addit
short
consent
form
use
document
subject
consent
option
inject
inactiv
licens
monoval
influenza
vaccin
elig
requir
licens
vaccin
inject
subject
consent
contraind
licens
inactiv
influenza
vaccin
contraind
addit
research
blood
draw
visit
assess
princip
investig
subject
must
meet
follow
criteria
year
old
avail
clinic
followup
week
abl
provid
proof
ident
satisfact
studi
clinician
complet
enrol
process
complet
aou
prior
enrol
verbal
understand
question
answer
incorrectli
abl
will
complet
inform
consent
process
will
donat
blood
sampl
storag
use
futur
research
male
partner
previous
undergon
vasectomi
subject
exclud
one
follow
condit
appli
women
specif
breastfeed
plan
becom
pregnant
first
week
enrol
studi
asthma
sever
unstabl
requir
emerg
care
urgent
care
hospit
intub
past
two
year
requir
use
oral
intraven
high
dose
inhal
corticosteroid
diabet
mellitu
type
thyroid
diseas
wellcontrol
gener
idiopath
urticaria
within
last
year
hypertens
well
control
medic
enrol
bleed
disord
diagnos
doctor
eg
factor
defici
coagulopathi
platelet
disord
requir
special
precaut
signific
bruis
bleed
malign
activ
treat
malign
reason
assur
sustain
cure
malign
like
recur
period
studi
seizur
disord
febril
seizur
seizur
secondari
alcohol
withdraw
year
ago
seizur
requir
treatment
within
last
year
asplenia
function
asplenia
condit
result
absenc
remov
spleen
syndrom
psychiatr
condit
preclud
complianc
protocol
past
present
psychos
past
present
bipolar
disord
disord
requir
lithium
within
year
prior
enrol
histori
suicid
plan
attempt
medic
psychiatr
social
condit
occup
reason
respons
judgment
investig
contraind
protocol
particip
impair
volunt
abil
give
inform
consent
evalu
vaccin
safeti
includ
laboratori
studi
medic
histori
physic
assess
clinician
subject
selfassess
record
diari
card
day
follow
studi
inject
potenti
advers
reaction
evalu
prior
continu
immun
schedul
blood
test
immun
respons
perform
vrc
satellit
facil
studi
schedul
describ
section
present
form
tabl
appendix
iii
total
blood
volum
drawn
subject
exceed
nih
clinic
center
guidelin
screen
studi
complet
vrc
infecti
diseas
vaccin
screen
protocol
vrc
nih
test
done
accord
elig
criteria
clinic
assess
screen
screen
evalu
specif
elig
criteria
see
section
must
complet
within
time
interv
specifi
prior
enrol
may
repeat
need
confirm
elig
storag
sampl
peripher
blood
mononuclear
cell
pbmc
serum
also
collect
screen
although
gener
collect
day
prior
enrol
particular
interv
time
prior
enrol
collect
sampl
specifi
day
defin
day
vrc
enrol
first
inject
vrc
elig
review
day
part
enrol
process
elig
evalu
conduct
screen
visit
vrc
routin
use
elig
screen
occur
within
specifi
window
prior
day
visit
howev
clinic
assess
day
suggest
signific
chang
may
occur
sinc
screen
visit
physic
examin
hematolog
test
blood
chemistri
done
day
must
use
elig
pregnanc
test
result
women
reproduct
potenti
must
obtain
inject
day
prior
studi
inject
day
evalu
prior
first
inject
baselin
subsequ
safeti
assess
vaccin
administ
nonblind
subject
receiv
formul
dose
investig
product
vaccin
studi
identif
number
provid
follow
enrol
prior
order
day
vaccin
site
pharmaci
inject
day
prior
inject
studi
subject
evalu
clinic
blood
sampl
immunolog
assay
also
collect
prior
inject
recommend
requir
first
inject
administ
nondomin
arm
prefer
requir
arm
altern
studi
inject
choos
arm
inject
clinician
consid
whether
arm
injuri
local
skin
problem
signific
tattoo
preclud
administ
inject
interfer
evalu
arm
inject
day
dna
vaccin
mg
dosag
administ
deltoid
muscl
ml
volum
use
biojector
needlefre
inject
system
biojector
bioject
medic
technolog
inc
portland
biojector
use
direct
manufactur
biojector
use
steril
singleus
syring
administr
volum
ml
studi
agent
deliv
pressur
compress
co
ga
cartridg
store
insid
biojector
neither
materi
inject
inject
site
skin
prepar
requir
deviat
standard
procedur
co
come
contact
inject
syring
design
prevent
back
splatter
contamin
devic
tissu
particip
follow
studi
inject
subject
remain
clinic
minimum
minut
vital
sign
temperatur
blood
pressur
puls
respiratori
rate
taken
minut
postinject
inject
site
inspect
evid
local
reaction
keep
nih
clinic
center
polici
good
medic
practic
acut
medic
care
provid
subject
immedi
allerg
reaction
injuri
result
particip
research
studi
vaccin
administ
accord
packag
insert
licens
vaccin
subject
given
diari
card
use
memori
aid
record
temperatur
symptom
daili
day
subject
train
use
secur
databas
complet
paper
diari
card
depend
prefer
diari
card
paramet
record
directli
subject
passwordprotect
secur
databas
subject
electron
record
sourc
data
written
paper
diari
card
may
use
sourc
document
neither
written
electron
diari
card
avail
subject
studi
clinician
note
sourc
reactogen
inform
record
studi
databas
followup
subject
wellb
perform
telephon
first
second
day
follow
inject
clinic
visit
schedul
indic
telephon
interview
event
report
telephon
interview
requir
clinic
visit
includ
rash
urticaria
fever
grade
higher
last
greater
hour
signific
impair
activ
daili
live
adl
addit
clinic
concern
may
prompt
studi
visit
base
judgment
studi
clinician
skin
lesion
inject
site
occur
studi
may
ask
subject
allow
us
take
photograph
subject
agre
hesh
ask
sign
nih
clinic
center
consent
photographi
form
day
deviat
visit
window
complet
studi
visit
studi
inject
discourag
record
protocol
deviat
permit
discret
pi
designe
interest
complet
vaccin
schedul
obtain
subject
safeti
immunogen
evalu
follow
exposur
investig
vaccin
schedul
shown
appendix
iii
target
schedul
effort
made
stay
close
possibl
schedul
howev
time
administr
option
licens
inactiv
inject
discret
princip
investig
given
uncertainli
suppli
avail
import
studi
subject
public
health
administ
earliest
mutual
agreeabl
time
subject
studi
week
licens
inactiv
vaccin
becom
avail
administr
protocol
vrc
assess
understand
quiz
signatur
studi
particip
inform
consent
form
vrc
clinic
evalu
vital
sign
target
physic
exam
visit
indic
interim
complaint
laboratori
find
interim
medic
histori
includ
immun
statu
approxim
time
immun
current
season
influenza
vaccin
counsel
avoid
pregnanc
women
reproduct
potenti
postinject
vital
sign
assess
inject
site
minut
postinject
diari
card
baselin
day
inject
diari
card
selfassess
subject
follow
studi
inject
diari
card
includ
paramet
unusu
tiredfeel
unwel
muscl
ach
inject
site
headach
chill
nausea
paintend
inject
site
subject
also
record
highest
measur
temperatur
measur
perpendicular
diamet
red
swell
inject
site
complet
diari
card
collect
first
visit
follow
complet
collect
realtim
secur
webbas
subject
data
entri
system
depend
prefer
subject
serum
urin
pregnanc
test
femal
reproduct
potenti
subject
becom
pregnant
subject
contact
followup
inform
regard
outcom
pregnanc
human
leukocyt
antigen
hla
avail
result
prior
test
perform
nih
clinic
center
may
record
high
resolut
mhc
class
class
ii
order
blood
creatinin
alt
influenzaspecif
antibodi
measur
hai
assay
note
assay
perform
immedi
rather
complet
use
frozen
sampl
later
date
indic
assay
may
perform
store
sera
timepoint
ic
elispot
assay
done
exploratori
analys
store
sampl
plasma
pbmc
collect
store
assay
may
use
exploratori
laboratori
assay
serum
archiv
varieti
exploratori
immunogen
evalu
cell
serum
plasma
use
store
futur
virolog
immunolog
assay
store
sampl
may
use
later
elucid
genet
factor
associ
immun
respons
vaccin
evalu
respons
vaccin
concomit
medic
review
elig
record
screen
everi
studi
visit
fdaapprov
live
attenu
vaccin
requir
recommend
given
least
week
first
week
third
studi
inject
enrol
fdaapprov
subunit
kill
vaccin
requir
immedi
medic
need
recommend
given
least
day
first
day
third
studi
inject
imperil
subject
health
fdaapprov
vaccin
defer
visit
schedul
week
final
studi
inject
complet
recommend
avoid
potenti
effect
immunogen
analysi
schedul
protocol
involv
three
inject
investig
influenza
vaccin
subject
discontinu
inject
follow
safeti
immunogen
accord
schedul
appendix
iii
reason
discontinu
pregnanc
followup
contact
schedul
record
outcom
pregnanc
specif
event
requir
withdraw
subject
inject
schedul
includ
follow
pregnanc
immedi
hypersensit
reaction
associ
studi
inject
intercurr
ill
expect
resolv
prior
next
schedul
studi
inject
assess
studi
clinician
requir
withdraw
inject
schedul
treatment
immunomodul
nonsteroid
antiinflammatori
drug
nsaid
reason
except
short
cours
system
glucocorticoid
complet
least
day
prior
next
inject
criteria
withdraw
irb
fda
request
studi
stop
princip
investig
close
monitor
analyz
studi
data
becom
avail
make
determin
regard
presenc
sever
advers
event
administr
studi
inject
new
enrol
paus
evalu
unexpect
potenti
safeti
concern
relat
investig
dna
vaccin
ind
sponsor
promptli
notifi
accord
follow
criteria
one
subject
experi
grade
grade
advers
event
assess
possibl
probabl
definit
relat
studi
vaccin
two
subject
experi
grade
advers
event
assess
possibl
probabl
definit
relat
studi
vaccin
studi
inject
enrol
would
resum
review
advers
event
caus
paus
result
recommend
permit
studi
inject
studi
enrol
review
make
decis
occur
follow
ind
sponsor
particip
princip
investig
consult
fda
conduct
review
make
decis
resum
close
studi
grade
grade
advers
event
meet
criteria
paus
studi
ind
sponsor
consult
princip
investig
conduct
review
make
decis
resum
close
studi
grade
event
meet
criteria
paus
studi
part
paus
review
review
also
advis
whether
studi
need
paus
subsequ
grade
event
type
safeti
data
report
chang
studi
statu
submit
irb
promptli
accord
section
institut
polici
advers
event
ae
unfavor
unintend
chang
bodi
structur
bodi
function
laboratori
result
associ
tempor
use
studi
treatment
whether
consid
relat
studi
treatment
advers
event
grade
accord
tabl
grade
sever
advers
event
see
appendix
iv
report
ae
occur
period
particip
enrol
day
final
dna
indic
time
period
sae
detail
section
new
chronic
medic
condit
influenza
influenzalik
ill
record
last
studi
visit
subject
receiv
second
third
option
licens
inactiv
studi
inject
ae
report
day
last
inject
receiv
sae
detail
section
new
chronic
medic
condit
influenza
influenzalik
ill
record
last
studi
visit
term
seriou
advers
drug
experi
defin
cfr
follow
advers
drug
experi
occur
dose
result
follow
outcom
death
lifethreaten
advers
drug
experi
inpati
hospit
prolong
exist
hospit
persist
signific
disabilityincapac
congenit
anomalybirth
defect
import
medic
event
may
result
death
lifethreaten
requir
hospit
may
consid
seriou
advers
drug
experi
base
upon
appropri
medic
judgment
may
jeopard
subject
requir
medic
surgic
intervent
prevent
one
outcom
list
definit
exampl
medic
event
includ
allerg
bronchospasm
requir
intens
treatment
emerg
room
home
blood
dyscrasia
convuls
result
inpati
hospit
develop
drug
depend
drug
abus
lifethreaten
refer
advers
event
occurr
repres
immedi
risk
death
subject
event
may
caus
death
occur
sever
form
consid
lifethreaten
similarli
hospit
admiss
elect
procedur
consid
seriou
advers
event
sae
inform
advers
event
collect
research
nurs
clinic
staff
enter
comput
databas
ae
data
review
ongo
basi
studi
coordin
princip
investig
advers
experi
meet
sae
report
requir
must
report
princip
investig
designe
rchspp
clinic
safeti
offic
repres
ind
sponsor
advers
event
determin
seriou
base
outcom
advers
event
briefli
summar
event
requir
complet
sae
report
form
includ
follow
outcom
regardless
assess
relationship
studi
agent
inpati
hospit
prolong
exist
hospit
elect
reason
import
medic
event
may
immedi
lifethreaten
result
death
hospit
may
jeopard
patientstudi
subject
may
requir
intervent
prevent
one
outcom
list
purpos
protocol
spontan
abort
report
sae
death
lifethreaten
sae
due
caus
occur
cours
studi
must
report
rchspb
clinic
safeti
offic
within
busi
day
princip
investig
designe
becom
awar
event
sae
report
must
submit
rchspb
soon
possibl
later
work
day
princip
investig
designe
becom
awar
event
meet
criteria
sae
follow
resolut
princip
investig
deem
event
chronic
subject
stabl
rchspb
clinic
safeti
offic
contact
phone
fax
email
rchspsafeti
mailnihgov
ind
sponsor
respons
submit
ind
safeti
report
fda
necessari
per
cfr
ind
sponsor
notifi
fda
within
calendar
day
receipt
inform
death
lifethreaten
event
meet
expedit
report
requir
report
rchspb
submit
ind
safeti
report
soon
possibl
later
calendar
day
initi
receipt
inform
advers
event
report
requir
niaid
institut
review
board
irb
rockledg
drive
bethesda
md
protocol
follow
investig
submit
complet
seriou
advers
event
report
niaid
irb
within
day
becom
awar
subject
death
potenti
lifethreaten
grade
seriou
advers
event
possibl
probabl
definit
relat
investig
agent
inpati
hospit
elect
persist
signific
disabilityincapac
congenit
anomalybirth
defect
investig
report
within
day
event
condit
regardless
grade
judgment
repres
event
report
irb
investig
forward
ind
safeti
report
relat
fda
commun
irb
within
day
receipt
summari
advers
event
report
niaid
irb
submiss
request
continu
review
nih
institut
biosafeti
committe
ibc
build
room
nih
bethesda
md
respons
review
research
use
recombin
dna
complianc
nih
guidelin
keep
ibc
requir
sae
report
sent
irb
provid
ibc
studi
singlecent
trial
assess
safeti
toler
investig
influenza
dna
vaccin
administ
dose
mg
schedul
follow
option
immun
licens
inactiv
monoval
influenza
vaccin
exploratori
assess
immunogen
also
perform
primari
object
trial
concern
dna
vaccin
safeti
secondari
exploratori
object
concern
immunogen
vaccin
assess
product
safeti
includ
clinic
observ
monitor
hematolog
chemic
paramet
safeti
close
monitor
inject
evalu
clinic
visit
studi
week
see
section
appendix
iii
detail
specifi
time
point
follow
paramet
assess
local
reactogen
sign
symptom
system
reactogen
sign
symptom
laboratori
measur
safeti
advers
experi
day
last
studi
inject
seriou
advers
event
new
chronic
medic
condit
throughout
studi
immunogen
princip
immunogen
endpoint
haspecif
antibodi
respons
measur
hai
assay
exploratori
endpoint
haspecif
tcell
respons
measur
ic
assay
elispot
assay
hai
assay
endpoint
posit
respons
subject
defin
subject
achiev
rise
ha
hai
antibodi
titer
baselin
day
week
post
vaccin
subject
immun
baselin
titer
increas
titer
defin
seroprotect
subject
posit
titer
baselin
posit
titer
need
fold
higher
day
valu
defin
seroconvers
exploratori
endpoint
haspecif
tcell
respons
respons
consid
posit
increas
least
sfc
background
detect
elispot
assay
increas
baselin
ic
assay
cell
detect
subject
record
posit
respons
whenev
assay
week
inject
posit
neg
respons
whenev
assay
neg
exploratori
object
relat
evalu
humor
cellular
immun
respons
includ
evalu
respons
baselin
last
studi
visit
studi
design
enrol
healthi
adult
particip
age
subject
treat
openlabel
vaccin
investig
product
day
week
week
elig
studi
particip
offer
singl
option
booster
immun
licens
inactiv
monoval
influenza
vaccin
studi
week
visit
enrol
plan
includ
provis
replac
particip
incomplet
vaccin
visit
schedul
goal
safeti
evalu
studi
identifi
safeti
concern
associ
inject
investig
vaccin
primari
sampl
size
calcul
safeti
express
term
abil
detect
seriou
advers
experi
abil
studi
identifi
sae
express
term
probabl
observ
certain
number
seriou
advers
event
use
valu
minimum
true
event
rate
probabl
observ
least
one
event
least
maximum
true
event
rate
probabl
observ
event
least
within
vaccine
chanc
observ
least
sae
true
rate
least
chanc
observ
sae
true
rate
probabl
observ
seriou
advers
event
within
group
present
tabl
rang
possibl
true
event
rate
calcul
provid
complet
pictur
sensit
studi
design
identifi
potenti
safeti
problem
vaccin
tabl
applic
immunogen
respons
rate
give
exact
confid
interv
true
respons
rate
possibl
number
respons
vaccine
exampl
observ
respons
among
vaccine
exact
binomi
confid
interv
true
respons
rate
rang
tabl
give
probabl
observ
least
respons
rang
underli
respons
rate
exampl
true
respons
rate
particular
time
point
probabl
observ
least
one
respons
probabl
observ
least
two
respons
among
vaccine
studi
includ
one
group
treat
subject
therefor
statist
comparison
respons
rate
requir
sinc
enrol
concurr
receiv
first
studi
vaccin
particip
receiv
least
one
vaccin
therefor
provid
safeti
data
statist
analys
perform
use
statist
analysi
system
sa
r
splu
statist
softwar
analysi
variabl
consist
baselin
variabl
safeti
variabl
immunogen
variabl
primari
secondari
object
analys
baselin
characterist
includ
demograph
laboratori
measur
summar
use
descript
statist
number
percentag
particip
experienc
type
reactogen
sign
symptom
tabul
sever
given
sign
symptom
particip
reactogen
count
maximum
sever
assess
advers
experi
code
medic
dictionari
regulatori
activ
meddra
prefer
term
number
percentag
particip
experienc
specif
advers
event
tabul
sever
relationship
treatment
calcul
tabl
particip
advers
experi
count
maximum
sever
strongest
record
causal
relationship
treatment
complet
list
advers
experi
particip
provid
detail
includ
sever
relationship
treatment
onset
durat
outcom
boxplot
local
laboratori
valu
gener
baselin
valu
valu
measur
cours
studi
boxplot
show
quartil
median
rd
quartil
outlier
valu
outsid
boxplot
also
plot
appropri
horizont
line
repres
boundari
abnorm
valu
plot
statist
analysi
immunogen
employ
intenttotreat
principl
ie
data
enrol
particip
use
final
analysi
immunogen
case
subject
receiv
regimen
differ
assign
astreat
analysi
perform
assay
data
qualit
ie
posit
neg
analys
perform
tabul
frequenc
posit
respons
assay
time
point
assess
perform
binomi
respons
rate
present
correspond
exact
confid
interv
estim
miss
respons
assum
miss
random
ie
condit
observ
data
missing
independ
unobserv
respons
graphic
descript
longitudin
immun
respons
also
given
immunolog
assay
underli
continu
counttyp
readout
often
dichotom
respondernonrespond
categori
assay
graphic
tabular
summari
underli
distribut
made
summari
may
perform
transform
data
eg
log
transform
better
satisfi
assumpt
symmetri
homoscedast
interim
analysi
immunogen
may
perform
week
post
studi
inject
first
subject
report
provid
princip
investig
key
vrc
investig
sole
purpos
plan
futur
studi
time
manner
earli
interim
result
conduct
influenc
conduct
vrc
trial
term
earli
termin
later
safeti
immunogen
endpoint
assess
studi
number
use
sequenti
enrol
subject
studi
number
assign
complet
enrol
form
electron
studi
databas
studi
number
assign
day
studi
consent
sign
elig
confirm
vaccin
schedul
shown
tabl
refer
section
inform
manufactur
studi
agent
investig
studi
agent
may
ship
site
pharmaci
ind
vrc
assess
fda
safe
proceed
studi
includ
treatment
one
investig
vaccin
mgml
dna
vaccin
vaccin
mgml
administ
im
inject
volum
ml
via
biojector
deltoid
muscl
day
day
day
least
day
inject
licens
inactiv
monoval
influenza
vaccin
avail
nih
clinic
center
pharmaci
use
booster
inject
time
deliveri
studi
agent
pharmaci
label
studi
agent
dna
vaccin
specif
product
inform
eg
part
number
lot
number
fill
volum
storag
temperatur
includ
product
vial
label
label
contain
investig
use
statement
caution
new
drug
limit
feder
law
investig
use
manufactur
inform
inactiv
monoval
influenza
vaccin
label
manufactur
deviat
storag
temperatur
occur
normal
allow
pharmaci
freezer
site
pharmacist
must
report
storag
temperatur
excurs
promptli
pi
ind
sponsor
complianc
nih
clinic
center
polici
excurs
must
evalu
investig
action
must
taken
restor
maintain
desir
temperatur
limit
temperatur
excurs
outsid
normal
allow
storag
devic
product
kept
report
per
pharmaci
guidelin
pend
outcom
investig
ind
sponsor
notifi
pharmacist
continu
clinic
use
product
accept
upon
releas
vrc
dna
vaccin
vial
ship
within
recommend
temperatur
rang
use
appropri
ship
configur
studi
pharmacist
store
freezer
within
rang
storag
permit
stopper
limit
inactiv
monoval
influenza
vaccin
licens
vaccin
use
studi
store
accord
manufactur
specif
section
describ
site
pharmacist
prepar
dna
vaccin
inject
clinician
instruct
select
arm
administ
inject
section
dna
vaccin
suppli
ml
glass
vial
contain
clear
colorless
isoton
steril
solut
vial
contain
amount
inject
cgmp
grade
phosphatebuff
salin
vial
intend
singl
use
thu
contain
preserv
refrozen
thaw
vial
mgml
contain
volum
ml
mg
remov
vial
dna
vaccin
mgml
freezer
allow
vial
equilibr
room
temperatur
c
swirl
content
gentli
use
asept
techniqu
withdraw
ml
dna
vaccin
vial
biojector
syring
cap
syring
label
syring
subject
identifi
date
time
allow
administr
one
ml
inject
mgml
prepar
administ
mg
dose
dna
vaccin
dose
vaccin
prepar
clinic
center
pharmaci
prepar
biojector
syring
label
subject
identifi
deliv
vrc
clinic
administr
pharmaci
also
label
inform
date
time
prepar
may
use
inject
must
administ
within
hour
remov
vial
freezer
inactiv
monoval
influenza
vaccin
inactiv
monoval
influenza
vaccin
prepar
administ
accord
manufactur
specif
studi
pharmacist
respons
maintain
accur
record
inventori
account
record
investig
inactiv
licens
vaccin
suppli
studi
electron
document
well
paper
copi
use
singl
use
syring
inactiv
vaccin
obtain
multius
vial
use
portion
studi
agent
account
may
conduct
clinic
staff
multius
vial
transfer
clinic
empti
vial
investig
product
unus
portion
vial
discard
biohazard
contain
bag
inciner
autoclav
unopen
vial
remain
end
studi
discard
discret
vrc
accord
polici
appli
investig
agent
partial
use
vial
expir
prepar
dose
administ
subject
use
vitro
experiment
studi
discard
indic
inactiv
monoval
influenza
vaccin
dispos
accord
manufactur
specif
nih
clinic
center
pharmaci
practic
research
studi
conduct
complianc
protocol
good
clinic
practic
gcp
guidelin
applic
regulatori
requir
studi
inform
consent
consent
option
inject
licens
monoval
inactiv
influenza
vaccin
provid
appendix
studi
consent
describ
investig
product
use
aspect
involv
protocol
particip
subject
may
particip
studi
investig
respons
obtain
written
inform
consent
subject
adequ
explan
aim
method
anticip
benefit
potenti
hazard
studi
protocolspecif
procedur
studi
medic
administ
acquisit
inform
consent
document
subject
medic
record
requir
cfr
inform
consent
form
sign
person
date
subject
person
conduct
inform
consent
discuss
origin
sign
inform
consent
form
retain
medic
chart
copi
inform
consent
form
provid
subject
first
studi
human
dna
vaccin
risk
note
base
risk
earlier
dna
vaccin
studi
similar
vaccin
well
risk
vaccin
gener
result
previou
studi
investig
dna
vaccin
potenti
side
effect
result
intramuscular
inject
includ
sting
arm
discomfort
red
skin
mild
bruis
small
lacer
vaccin
inject
site
studi
subject
receiv
medic
acetaminophen
nsaid
antihistamin
requir
subject
may
exhibit
gener
sign
symptom
associ
administr
vaccin
inject
includ
fever
chill
rash
ach
pain
nausea
headach
dizzi
fatigu
side
effect
monitor
gener
short
term
requir
treatment
potenti
risk
dna
vaccin
includ
muscl
damag
antibodi
dna
insert
vaccin
dna
host
genom
dna
potenti
cancer
risk
insert
vaccin
dna
bacterium
viru
previou
vrc
dna
vaccin
studi
placebo
vaccin
recipi
note
occasion
asymptomat
selflimit
chang
laboratori
test
urticaria
report
infrequ
advers
event
possibl
relat
dna
vaccin
investig
dna
vaccin
administ
via
biojector
associ
mild
skin
lesion
cm
diamet
vaccin
site
case
small
scab
form
within
week
immun
came
day
skin
heal
without
treatment
within
week
one
skin
biopsi
obtain
day
post
vaccin
show
subcutan
dermal
perivascular
lymphocyt
inflamm
rare
eosinophil
rare
giant
cell
note
infiltr
compos
entir
posit
cell
includ
cell
process
appear
primarili
subcutan
inflammatori
respons
vaccin
cutan
manifest
may
unknown
side
effect
risk
inactiv
monoval
influenza
vaccin
describ
packag
insert
occasion
adult
recipi
inactiv
vaccin
may
develop
influenzalik
sign
symptom
fever
bodi
ach
headach
malais
myalgia
andor
nausea
usual
greatest
within
first
hour
vaccin
last
day
subject
may
experi
reactogen
site
vaccin
red
swell
pain
tender
analges
eg
ibuprofen
acetaminophen
rest
gener
reliev
moder
symptom
reaction
go
away
day
requir
addit
treatment
acut
potenti
lifethreaten
allerg
reaction
also
possibl
sinc
vaccin
may
contain
limit
quantiti
egg
protein
protein
induc
immedi
hypersensit
reaction
among
person
sever
egg
allergi
allerg
reaction
includ
hive
angioedema
allerg
asthma
system
anaphylaxi
egg
allergi
contraind
receiv
inactiv
vaccin
swine
influenza
vaccin
campaign
per
vaccin
recipi
develop
paralyt
ill
call
syndrom
seen
consist
influenza
vaccin
person
develop
recov
complet
vaccin
may
unknown
side
effect
effect
studi
vaccin
fetu
nurs
babi
unknown
femal
subject
reproduct
potenti
requir
agre
use
birth
control
sexual
intercours
begin
day
prior
enrol
continu
last
studi
visit
women
pregnant
nurs
exclud
studi
blood
draw
may
caus
pain
bruis
rare
infect
site
blood
taken
although
studi
subject
may
benefit
clinic
test
physic
examin
receiv
direct
health
benefit
studi
vaccin
other
may
benefit
knowledg
gain
studi
may
aid
develop
improv
influenza
viru
vaccin
regimen
copi
protocol
propos
inform
consent
form
written
subject
inform
propos
advertis
materi
submit
irb
written
approv
prior
implement
investig
must
submit
necessari
obtain
approv
irb
subsequ
protocol
amend
chang
inform
consent
document
investig
notifi
irb
deviat
protocol
seriou
advers
event
accord
irb
polici
investig
respons
obtain
irb
approv
annual
continu
review
throughout
durat
studi
investig
must
ensur
subject
anonym
maintain
subject
identifi
report
studi
record
kept
confidenti
extent
provid
feder
state
local
law
medic
record
made
avail
review
requir
fda
author
user
vaccin
manufactur
guidelin
set
feder
privaci
act
direct
access
includ
examin
analyz
verifi
reproduc
record
report
import
evalu
studi
investig
oblig
inform
subject
name
repres
review
studyrel
record
without
violat
confidenti
subject
store
studi
research
sampl
label
code
number
vrc
clinic
team
link
subject
requir
maintain
subject
confidenti
includ
studi
inform
consent
document
june
memorandum
research
use
store
human
sampl
specimen
data
requir
nih
irbapprov
protocol
intramur
research
program
research
intend
collect
store
human
specimen
data
must
includ
written
descript
intend
use
sampl
store
track
happen
complet
protocol
circumst
would
prompt
pi
report
irb
loss
destruct
sampl
appli
specifi
provis
store
sampl
protocol
follow
intend
use
samplesspecimensdata
sampl
specimen
data
collect
protocol
may
use
conduct
protocolrel
safeti
immunogen
evalu
exploratori
laboratori
evalu
relat
type
infect
vaccin
design
prevent
exploratori
laboratori
evalu
relat
vaccin
research
gener
research
assay
valid
genet
test
may
perform
accord
genet
test
inform
includ
studi
inform
consent
store
sampl
specimen
data
sampl
use
store
store
studi
research
sampl
label
code
number
vrc
clinic
link
subject
sampl
store
niaid
vaccin
immun
tcell
antibodi
laboratori
nvital
gaithersburg
md
vrc
laboratori
build
secur
facil
limit
access
data
kept
passwordprotect
comput
investig
designe
access
sampl
data
samplesspecimensdata
track
sampl
track
laboratori
inform
manag
system
lim
databas
happen
samplesspecimensdata
complet
protocol
futur
investig
nih
outsid
may
wish
studi
sampl
andor
data
irb
approv
must
sought
prior
share
sampl
nonnih
investig
clinic
inform
share
sampl
would
similarli
requir
prior
irb
approv
research
use
store
unlink
unidentifi
sampl
may
exempt
need
prospect
irb
review
approv
exempt
request
submit
write
nih
offic
human
subject
research
author
determin
whether
research
activ
exempt
time
protocol
termin
sampl
remain
nvital
facil
vrc
laboratori
irb
approv
transfer
regulatori
oversight
omnibu
store
sampl
protocol
data
archiv
vrc
complianc
requir
retent
research
record
irb
studi
sponsor
approv
may
either
destroy
transfer
anoth
repositori
circumst
would
prompt
pi
report
loss
destruct
samplesspecimensdata
irb
nih
intramur
protocol
violat
definit
relat
loss
destruct
sampl
follow
report
irb
loss
unanticip
destruct
sampl
exampl
due
freezer
malfunct
data
exampl
misplac
printout
data
identifi
report
irb
pi
also
notifi
irb
decis
made
destroy
remain
sampl
studi
activ
carri
clinic
center
nih
approv
satellit
facil
studi
subject
recruit
onsit
offsit
advertis
done
screen
protocol
vrc
effort
made
includ
women
minor
proport
similar
commun
recruit
phase
studi
design
establish
safeti
vaccin
healthi
adult
enrol
limit
person
least
year
age
older
year
age
depart
health
human
servic
protect
children
particip
research
gener
healthi
children
studi
research
consid
greater
minim
risk
children
involv
research
greater
minim
risk
present
prospect
direct
benefit
individu
child
like
yield
generaliz
knowledg
child
disord
condit
subject
compens
time
inconveni
accord
standard
compens
clinic
research
volunt
program
compens
per
visit
visit
includ
inject
clinic
visit
includ
blood
draw
procedur
compens
clinic
visit
includ
blood
draw
procedur
approxim
total
compens
subject
base
number
schedul
studi
clinic
visit
approxim
visit
complet
option
inactiv
andor
followup
research
blood
draw
compens
rate
base
upon
visit
type
close
cooper
design
member
protocol
team
occur
evalu
respond
individu
advers
event
time
manner
vrc
safeti
offic
nurs
practition
physician
conduct
daili
safeti
review
clinic
data
per
vrc
clinic
practic
protocol
safeti
review
team
psrt
includ
design
team
member
princip
investig
associ
investig
studi
coordin
protocol
specialist
ind
sponsor
medic
monitor
studi
clinician
psrt
review
summari
studi
safeti
data
report
weekli
week
last
subject
receiv
final
studi
inject
order
certain
vaccin
accept
safeti
profil
continu
monitor
studi
safeti
data
report
least
monthli
basi
complet
last
week
visit
protocol
amend
must
made
prior
approv
vrc
niaid
rchspb
niaid
agreement
investig
must
obtain
protocol
amend
amend
inform
consent
document
studi
amend
submit
irb
approv
vrc
princip
investig
niaid
irb
rchspb
niaid
fda
reserv
right
termin
studi
investig
notifi
irb
write
studi
complet
earli
termin
investig
maintain
list
appropri
qualifi
person
trial
duti
deleg
sourc
document
origin
document
data
record
subject
data
obtain
includ
limit
hospit
record
clinic
offic
chart
investig
staff
respons
maintain
comprehens
central
file
system
studyrel
essenti
document
suitabl
inspect
time
repres
vrc
rchspb
irb
fda
andor
applic
regulatori
author
element
includ
subject
file
contain
complet
inform
consent
form
support
copi
sourc
document
kept
studi
file
contain
protocol
amend
investig
brochur
copi
correspond
irb
vrc
addit
origin
sourc
document
must
maintain
readili
avail
essenti
document
retain
institut
period
time
requir
medic
record
retent
fda
requir
studi
record
retain
two
year
market
approv
refus
cfr
studi
document
destroy
without
prior
written
agreement
rchspb
vrc
princip
investig
investig
wish
assign
studi
record
anoth
parti
move
anoth
locat
rchspb
must
notifi
write
new
respons
person
andor
new
locat
clinic
research
data
collect
secur
electron
webbas
data
manag
system
contract
research
organ
emm
rockvil
md
extract
data
without
patient
identifi
sent
protocol
statistician
statist
analysi
rchspb
niaid
vrc
regulatori
author
inspector
author
repres
respons
contact
visit
investig
purpos
inspect
facil
upon
request
inspect
variou
record
trial
provid
subject
confidenti
respect
site
investig
allow
studi
monitor
niaid
irb
fda
inspect
studi
document
eg
consent
form
drug
distribut
form
case
report
form
pertin
hospit
clinic
record
confirm
studi
data
site
visit
studi
monitor
made
accord
ind
sponsor
polici
monitor
follow
studi
oper
qualiti
data
collect
research
record
accuraci
timeli
data
enter
databas
determin
process
regulatori
requir
met
studi
monitor
visit
occur
initi
studi
interv
determin
ind
sponsor
conduct
studi
complet
studi
written
inform
materi
use
subject
investig
staff
must
use
vocabulari
languag
readili
understood
invit
take
part
research
studi
nation
institut
health
nih
first
want
know
take
part
nih
research
entir
voluntari
may
choos
take
part
may
withdraw
studi
time
either
case
lose
benefit
otherwis
entitl
howev
receiv
care
nih
must
take
part
studi
evalu
studi
particip
may
receiv
benefit
take
part
research
may
give
us
knowledg
may
help
peopl
futur
second
peopl
person
religi
ethic
belief
may
limit
kind
medic
research
treatment
would
want
receiv
blood
transfus
belief
pleas
discuss
nih
doctor
research
team
agre
studi
describ
research
studi
decid
take
part
pleas
take
much
time
need
ask
question
discuss
studi
anyon
nih
famili
friend
person
physician
health
profession
studi
experiment
vaccin
prevent
novel
type
influenza
flu
known
swine
flu
news
report
vaccin
experiment
approv
food
drug
administr
fda
prevent
flu
infect
fda
allow
use
research
main
purpos
studi
see
experiment
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
p
f
l
e
n
e
c
n
p
r
c
l
c
n
e
n
vaccin
safe
whether
side
effect
anoth
goal
studi
blood
sampl
laboratori
immun
respons
elig
particip
studi
complet
screen
process
complet
assess
understand
year
old
blood
urin
test
result
meet
elig
requir
signific
medic
problem
determin
screen
swine
influenza
vaccin
campaign
per
vaccin
recipi
develop
paralyt
ill
call
syndrom
seen
consist
influenza
vaccin
person
develop
syndrom
recov
complet
condit
elig
particip
studi
studi
plan
enrol
peopl
studi
studi
done
vaccin
research
center
vrc
studi
visit
occur
nih
clinic
center
approv
satellit
locat
studi
particip
last
week
person
studi
monitor
vaccinerel
side
effect
studi
studi
inject
shot
given
peopl
upper
arm
inject
given
nih
clinic
center
told
new
inform
learn
studi
might
caus
chang
mind
stay
studi
end
studi
told
studi
result
may
avail
learn
vaccin
substanc
use
tri
creat
resist
immun
diseas
prevent
infect
get
flu
infect
vaccin
studi
contain
influenza
viru
studi
vaccin
experiment
vaccin
may
protect
get
flu
infect
one
swine
flu
vaccin
may
wide
avail
gener
public
fall
dna
vaccin
vaccin
made
protein
inject
muscl
protein
natur
substanc
bodi
use
build
block
dna
serv
natur
code
instruct
protein
product
bodi
new
kind
experiment
vaccin
test
studi
made
dna
code
novel
influenza
protein
steril
prepar
salt
water
solut
studi
dna
vaccin
inject
muscl
instruct
bodi
make
small
amount
influenza
protein
studi
vaccin
develop
nih
made
vaccin
manufactur
plant
frederick
maryland
first
time
dna
vaccin
given
peopl
twenti
healthi
adult
year
old
enrol
studi
inject
given
upper
arm
muscl
receiv
three
inject
studi
day
first
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
dna
vaccin
inject
given
use
needleless
system
call
biojector
devic
deliv
vaccin
skin
without
use
needl
use
pressur
carbon
dioxid
instead
needl
inject
vaccin
skin
muscl
needleless
system
use
sinc
deliv
vaccin
type
drug
system
fda
clearanc
deliv
vaccin
inject
muscl
plan
clinic
visit
studi
enrol
day
studi
week
studi
investig
vaccin
requir
follow
set
schedul
inject
followup
visit
order
answer
studi
research
question
flexibl
schedul
permit
import
work
staff
stay
schedul
visit
usual
take
hour
except
day
receiv
inject
day
visit
take
hour
clinic
staff
observ
least
minut
vaccin
one
two
day
inject
must
telephon
clinic
staff
report
ask
complet
diari
card
home
requir
record
temperatur
symptom
look
inject
site
day
ask
record
symptom
daili
day
report
side
effect
one
studi
physician
nurs
soon
possibl
clinic
staff
avail
phone
hour
day
may
record
symptom
paper
diari
card
enter
secur
electron
form
use
internet
choos
report
symptom
internet
train
clinic
staff
given
usernam
password
symptom
may
necessari
come
studi
clinic
examin
next
schedul
visit
import
follow
instruct
given
clinic
staff
visit
check
health
chang
problem
sinc
last
visit
ask
feel
taken
medic
includ
pill
inject
overthecount
medic
herbal
supplement
skin
medic
inhal
form
medic
emerg
call
studi
nurs
doctor
start
new
medicin
get
vaccin
shot
type
blood
drawn
schedul
studi
visit
urin
sampl
collect
check
health
need
told
promptli
test
result
show
health
problem
blood
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
p
f
l
e
n
e
c
n
p
r
c
l
c
n
e
n
sampl
use
studi
immun
respons
vaccin
result
immun
respons
test
test
use
check
health
given
studi
amount
blood
drawn
vari
tablespoon
ml
tablespoon
ml
depend
visit
plan
blood
draw
might
also
ask
laboratori
test
regular
visit
need
evalu
chang
health
seriou
side
effect
studi
physician
may
decid
receiv
inject
howev
ask
continu
studi
followup
visit
even
get
full
set
inject
ask
continu
blood
urin
test
monitor
health
complet
blood
draw
done
research
lab
test
studi
monitor
group
physician
scientist
clinic
center
group
review
inform
studi
pay
close
attent
harm
reaction
decid
signific
reaction
occur
inject
may
delay
cancel
blood
drawn
part
studi
use
genet
test
done
research
purpos
genet
test
may
help
research
see
peopl
differ
gene
differ
immun
respons
vaccin
genet
test
done
research
lab
store
sampl
name
identifi
inform
test
result
research
lab
medic
record
hla
type
genet
test
order
nih
clinic
center
medic
laboratori
done
regular
medic
laboratori
hla
type
result
medic
record
nih
clinic
center
hla
type
particular
genet
test
medic
record
detail
test
provid
blood
drawn
part
studi
use
test
hla
type
hla
like
genet
fingerprint
made
protein
play
import
role
immun
system
respond
foreign
organ
research
hla
test
sometim
use
tri
identifi
factor
associ
respons
vaccin
progress
diseas
relat
condit
determin
hla
type
necessari
abl
perform
certain
research
studi
hla
type
associ
increas
risk
certain
diseas
like
arthriti
rheumatolog
problem
simpli
hla
type
howev
nt
mean
develop
diseas
genet
test
also
use
determin
peopl
directli
relat
test
sometim
show
peopl
adopt
biolog
parent
someon
legal
parent
fact
known
previous
could
troubl
addit
genet
counsel
advic
avail
nation
institut
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
polici
discuss
inform
unless
direct
medic
reproduct
implic
famili
agre
particip
studi
waiv
right
may
regard
access
disclosur
record
inform
right
contact
princip
investig
studi
genet
inform
collect
discov
famili
confidenti
result
hla
test
becom
part
medic
record
nih
medic
record
contain
inform
maintain
secur
manner
genet
inform
reveal
other
includ
rel
without
permiss
releas
inform
famili
insur
compani
employ
unless
sign
document
allow
releas
inform
request
result
hla
genet
research
test
result
discuss
physician
notifi
result
genet
test
result
unless
known
current
medic
practic
medic
care
need
possibl
genet
research
test
plan
conduct
current
use
medic
practic
result
test
use
make
health
care
decis
particip
studi
blood
sampl
collect
alreadi
explain
store
sampl
futur
research
learn
influenza
viru
vaccin
immun
system
andor
medic
condit
result
research
done
store
sampl
given
health
care
provid
put
medic
record
test
result
unlik
routin
medic
test
experiment
mean
whether
mean
health
unknown
request
howev
result
research
test
discuss
physician
may
particip
studi
will
blood
sampl
store
futur
analysi
store
sampl
label
code
number
studi
team
link
identifi
inform
kept
confidenti
extent
permit
law
greatest
risk
unplan
releas
inform
medic
record
chanc
inform
given
unauthor
person
without
permiss
small
possibl
problem
unplan
releas
inform
includ
discrimin
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
p
f
l
e
n
e
c
n
p
r
c
l
c
n
e
n
appli
insur
employ
similar
problem
may
occur
disclos
inform
agre
medic
record
releas
futur
investig
nih
outsid
nih
may
wish
studi
store
sampl
studi
team
share
store
sampl
mark
code
identifi
inform
inform
gender
age
health
histori
ethnic
may
also
share
investig
futur
research
studi
use
sampl
review
investig
institut
review
board
irb
special
committe
overse
medic
research
studi
protect
right
welfar
human
subject
store
materi
use
research
sold
research
done
materi
may
use
develop
new
product
futur
receiv
payment
product
inject
risk
may
experi
mild
discomfort
inject
may
sting
arm
discomfort
pain
sore
red
swell
bruis
small
cut
skin
risk
faint
small
chanc
infect
inject
site
ask
record
report
side
effect
experi
may
need
make
extra
visit
clinic
evalu
side
effect
may
use
overthecount
nonprescript
pain
medic
need
possibl
risk
vaccin
gener
includ
fever
chill
rash
ach
pain
nausea
headach
dizzi
fatigu
know
side
effect
occur
vaccin
side
effect
nt
usual
last
long
vaccin
drug
could
immedi
allerg
reaction
includ
rash
hive
even
difficulti
breath
allerg
reaction
life
threaten
therefor
clinic
staff
watch
least
minut
immun
provid
need
treatment
may
side
effect
even
seriou
one
nt
know
yet
import
report
side
effect
clinic
staff
soon
occur
theori
risk
relat
dna
vaccin
gener
might
includ
muscl
damag
antibodi
dna
lead
ill
insert
vaccin
dna
bodi
dna
lead
cancer
dna
bacteria
viru
bodi
none
possibl
risk
dna
vaccin
seen
laboratori
test
anim
human
far
need
awar
possibl
risk
studi
dna
vaccin
group
start
earli
vrc
began
first
clinic
trial
dna
vaccin
studi
investig
dna
vaccin
develop
vrc
complet
nih
clinic
center
clinic
site
around
world
experi
far
peopl
dna
vaccin
made
vrc
vaccin
safe
welltoler
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
condit
possibl
relat
vaccin
experiment
dna
vaccin
includ
temporari
low
white
blood
cell
count
skin
rash
hive
hive
kind
allerg
reaction
subject
studi
dna
vaccin
similar
one
studi
protocol
develop
hive
itch
skin
welt
within
hour
mani
day
vaccin
need
treat
medicin
temporari
chang
blood
test
also
seen
known
chang
laboratori
test
relat
vaccin
due
caus
pattern
eat
drink
ill
daytoday
variat
laboratori
test
result
chang
lab
test
also
seen
peopl
got
placebo
inject
chang
requir
treatment
studi
regular
blood
test
checkup
perform
monitor
gener
health
reaction
vaccin
blood
store
studi
case
addit
safeti
test
need
sometim
dna
vaccin
inject
biojector
small
red
bump
scab
seen
form
inject
site
scab
less
inch
across
deep
infect
skin
heal
without
need
treatment
may
unknown
side
effect
risk
blood
draw
blood
drawn
vein
arm
use
needl
blood
draw
may
caus
pain
bruis
rare
infect
place
blood
taken
sometim
draw
blood
caus
peopl
feel
lighthead
even
faint
know
possibl
effect
investig
dna
vaccin
fetu
nurs
infant
research
studi
women
may
abl
becom
pregnant
ask
practic
adequ
birth
control
begin
least
day
prior
receiv
first
inject
last
studi
visit
pregnanc
test
immun
adequ
method
birth
control
includ
condom
male
femal
without
spermicid
diaphragm
cervic
cap
spermicid
intrauterin
devic
prescript
method
contracept
pill
patch
prescript
method
male
partner
previous
undergon
vasectomi
pregnant
breastfeed
want
becom
pregnant
next
six
month
particip
must
notifi
clinic
staff
immedi
upon
learn
becom
pregnant
studi
must
also
notifi
clinic
suspect
might
pregnant
studi
becom
pregnant
ask
continu
followup
amount
blood
drawn
reduc
contact
ask
outcom
pregnanc
safeti
vaccin
studi
unknown
unknown
studi
vaccin
may
alter
respons
futur
infect
may
influenza
virus
made
awar
signific
health
effect
vaccin
seriou
side
effect
occur
subject
updat
trial
need
may
donat
blood
blood
bank
particip
investig
vaccin
studi
one
year
date
last
inject
investig
vaccin
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
p
f
l
e
n
e
c
n
p
r
c
l
c
n
e
n
studi
design
benefit
one
know
investig
vaccin
work
prevent
influenza
other
may
benefit
futur
inform
learn
studi
cost
particip
studi
medic
cost
outsid
studi
paid
health
insur
carrier
insur
particip
receiv
compens
consist
niaid
polici
help
transport
cost
expens
may
occur
studi
particip
possibl
may
expens
cover
compens
provid
compens
visit
includ
inject
includ
blood
draw
inject
visit
visit
includ
inject
blood
draw
compens
approxim
total
compens
base
number
studi
visit
attend
studi
inject
receiv
paid
throughout
studi
visit
reimburs
travel
subsist
offer
consist
nih
guidelin
may
stop
receiv
studi
vaccin
sever
differ
reason
includ
nt
keep
appoint
follow
studi
procedur
studi
sponsor
studi
doctor
decid
stop
cancel
studi
regulatori
board
fda
decid
studi
stop
get
seriou
ill
need
receiv
certain
treatment
medic
neg
affect
immun
system
seriou
side
effect
thought
due
vaccin
becom
pregnant
agre
take
part
studi
import
keep
appoint
howev
nt
want
stay
studi
leav
time
lose
benefit
would
join
studi
studi
vaccin
complet
reason
ask
continu
followup
visit
end
studi
import
continu
monitor
health
even
receiv
three
vaccin
studi
design
treat
diseas
may
choos
particip
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
p
f
l
e
n
e
c
n
p
r
c
l
c
n
e
n
nation
institut
health
review
nih
staff
research
least
yearli
conflict
interest
follow
link
contain
detail
process
http
ethicsodnihgovformsprotocolreviewguidepdf
may
ask
research
team
addit
inform
copi
protocol
review
guid
conflict
interest
identifi
princip
research
staff
studi
protocol
may
investig
nih
employe
nonnih
investig
expect
adher
principl
protocol
review
guid
requir
report
person
financi
hold
nih
one
investig
particip
studi
may
less
stock
manufactur
product
use
studi
feder
regul
howev
permiss
creat
conflict
interest
nation
institut
health
includ
member
vaccin
research
center
scientif
staff
develop
investig
dna
vaccin
use
research
studi
result
studi
could
play
role
whether
fda
approv
vaccin
sale
time
futur
approv
futur
sale
vaccin
could
lead
payment
nih
nih
scientist
us
law
govern
scientist
requir
receiv
payment
invent
receiv
money
develop
sale
product
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
result
nih
research
studi
report
medic
journal
scientif
meet
peopl
take
part
name
identifi
case
nih
releas
inform
research
involv
without
written
permiss
howev
sign
releas
inform
form
exampl
insur
compani
nih
give
insur
compani
inform
medic
record
inform
might
affect
either
favor
unfavor
willing
insur
compani
sell
insur
feder
privaci
act
protect
confidenti
nih
medic
record
howev
know
act
allow
releas
inform
medic
record
without
permiss
exampl
requir
food
drug
administr
fda
member
congress
law
enforc
offici
author
peopl
vaccin
manufactur
studi
sponsor
clinic
center
provid
shortterm
medic
care
injuri
result
particip
research
gener
longterm
medic
care
financi
compens
researchrel
injuri
provid
nation
institut
health
clinic
center
feder
govern
howev
right
pursu
legal
remedi
believ
injuri
justifi
action
receiv
copi
vaccin
inform
sheet
avail
us
center
diseas
control
prevent
cdc
inactiv
inject
given
upper
arm
muscl
needl
syring
standard
licens
dose
adult
addit
clinic
visit
consent
enrol
studi
ask
complet
addit
visit
one
inactiv
inject
followup
visit
week
week
inject
studi
inject
ask
complet
diari
card
either
paper
electron
amount
blood
drawn
vari
tablespoon
ml
tablespoon
ml
depend
visit
might
also
ask
laboratori
test
regular
visit
need
evalu
chang
health
vaccin
inject
may
occur
extra
visit
visit
alreadi
studi
schedul
followup
research
blood
sampl
collect
schedul
week
week
vaccin
occasion
adult
recipi
inactiv
influenza
vaccin
may
develop
flulik
symptom
fever
bodi
ach
headach
fatigu
muscl
pain
andor
nausea
symptom
usual
greatest
within
first
hour
vaccin
may
last
day
peopl
may
develop
symptom
site
u
l
p
e
n
r
p
r
e
n
f
r
n
r
p
e
n
studi
number
vrc
continu
page
page
u
l
p
r
c
p
n
r
p
r
e
n
f
r
n
r
p
r
c
p
n
n
h
p
f
l
e
n
e
c
n
p
r
c
l
c
n
e
n
vaccin
red
swell
pain
tender
overthecount
pain
medic
eg
ibuprofen
acetaminophen
rest
gener
reliev
symptom
symptom
go
away
day
usual
requir
addit
treatment
swine
influenza
vaccin
campaign
per
vaccin
recipi
develop
paralyt
ill
usual
start
numb
leg
call
syndrom
condit
seen
consist
influenza
vaccin
swine
flu
vaccin
differ
one
given
current
person
develop
syndrom
recov
complet
ever
condit
elig
particip
studi
potenti
lifethreaten
allerg
reaction
vaccin
compon
possibl
sinc
vaccin
may
contain
limit
quantiti
egg
protein
protein
induc
immedi
hypersensit
reaction
among
person
sever
allergi
allerg
reaction
includ
hive
swell
allerg
asthma
spread
rapidli
may
unknown
side
effect
licens
vaccin
approv
fda
prevent
influenza
receiv
may
protect
type
flu
howev
may
receiv
benefit
take
part
part
studi
research
may
give
us
knowledg
may
help
peopl
futur
studi
inform
consent
sign
join
studi
includ
inform
follow
topic
studi
risk
collect
use
store
sampl
genet
test
inform
enrol
studi
consent
also
appli
agre
get
licens
vaccin
extra
research
blood
collect
studi
clinician
review
inform
consent
receiv
option
inactiv
vaccin
inject
consent
inactiv
vaccin
inject
compens
extra
visit
alreadi
schedul
includ
inject
includ
research
blood
draw
visit
includ
inject
approxim
total
addit
compens
may
result
nih
research
studi
report
medic
journal
scientif
meet
peopl
take
part
name
identifi
case
nih
releas
inform
research
involv
without
written
permiss
howev
sign
releas
inform
form
exampl
insur
compani
nih
give
insur
compani
inform
medic
record
inform
might
affect
either
favor
unfavor
willing
insur
compani
sell
insur
feder
privaci
act
protect
confidenti
nih
medic
record
howev
know
act
allow
releas
inform
medic
record
without
permiss
exampl
requir
food
drug
administr
fda
member
congress
law
enforc
offici
author
peopl
vaccin
manufactur
studi
sponsor
clinic
center
provid
shortterm
medic
care
injuri
result
particip
research
gener
longterm
medic
care
financi
compens
researchrel
injuri
provid
nation
institut
health
clinic
center
feder
govern
howev
right
pursu
legal
remedi
believ
injuri
justifi
action
comparison
assess
whether
futur
vrc
vaccin
studi
use
sever
grade
tabl
issu
fda
guidanc
document
http
wwwfdagovcbergdlnstoxvachtm
advers
event
studi
also
score
guidanc
document
tabl
howev
sever
grade
use
formal
regulatori
report
appli
paus
rule
sae
report
rule
comparison
sever
grade
two
tabl
done
oper
research
purpos
inform
futur
practic
addit
record
sever
advers
event
record
includ
attribut
assess
use
follow
categori
definit
definit
relat
advers
event
administr
studi
agent
relat
time
direct
associ
demonstr
probabl
relat
advers
event
administr
studi
agent
reason
relat
time
advers
event
like
explain
studi
agent
caus
possibl
relat
advers
event
administr
studi
agent
reason
relat
time
advers
event
explain
equal
well
caus
studi
agent
probabl
notunlik
relat
potenti
relationship
studi
agent
advers
event
could
exist
ie
possibl
exclud
advers
event
like
explain
caus
studi
agent
unrel
advers
event
clearli
explain
anoth
caus
relat
studi
agent
sever
ae
could
fall
either
one
two
grade
eg
sever
ae
could
either
grade
grade
select
higher
two
grade
ae
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
lower
limit
normal
medic
intervent
use
pharmacolog
biolog
agent
treatment
ae
amend
ptt
seizur
grade
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
basic
selfcar
function
young
children
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
amend
ptt
seizur
grade
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
basic
selfcar
function
young
children
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
amend
ptt
seizur
grade
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
basic
selfcar
function
young
children
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
amend
ptt
seizur
grade
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
basic
selfcar
function
young
children
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
adapt
task
desir
activ
go
work
shop
cook
use
transport
pursu
hobbi
etc
usual
social
function
activ
young
children
activ
age
cultur
appropri
eg
social
interact
play
activ
learn
task
etc
amend
ptt
seizur
grade
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
basic
selfcar
function
young
children
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
adapt
task
desir
activ
go
work
shop
cook
use
transport
pursu
hobbi
etc
usual
social
function
activ
young
children
activ
age
cultur
appropri
eg
social
interact
play
activ
learn
task
etc
amend
ptt
seizur
grade
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
basic
selfcar
function
young
children
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
adapt
task
desir
activ
go
work
shop
cook
use
transport
pursu
hobbi
etc
usual
social
function
activ
young
children
activ
age
cultur
appropri
eg
social
interact
play
activ
learn
task
etc
amend
ptt
seizur
grade
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
basic
selfcar
function
young
children
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
adapt
task
desir
activ
go
work
shop
cook
use
transport
pursu
hobbi
etc
usual
social
function
activ
young
children
activ
age
cultur
appropri
eg
social
interact
play
activ
learn
task
etc
amend
ptt
seizur
grade
basic
selfcar
function
adult
activ
bath
dress
toilet
transfermov
contin
feed
basic
selfcar
function
young
children
activ
age
cultur
appropri
eg
feed
self
cultur
appropri
eat
implement
adapt
task
desir
activ
go
work
shop
cook
use
transport
pursu
hobbi
etc
usual
social
function
activ
young
children
activ
age
cultur
appropri
eg
social
interact
play
activ
learn
task
etc
